

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/568,544
				Filing Date	September 22, 2006
				First Named Inventor	Kannagi
				Art Unit	1643
				Examiner Name	Meera Natarajan
Sheet	1	of	2	Attorney Docket Number	1680/12

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US-2002/164748	11-07-2002	Bistrup	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/568,544	
			Filing Date	September 22, 2006	
			First Named Inventor	Kannagi	
			Art Unit	1643	
Examiner Name	Meera Natarajan				
Sheet	2	of	2	Attorney Docket Number	1680/12

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2	Bruehl et al., "Minimal sulfated carbohydrates for recognition by L-selectin and the MECA-79 antibody," The Journal of Biological Chemistry, Vol. 275, No. 42, pgs. 32642-32648 (October 20, 2000).	
	3	Izawa et al., "Expression of sialyl 6-sulfo Lewis X is inversely correlated with conventional sialyl Lewis X expression in human colorectal cancer," Cancer Research, Vol. 60, No. 5, pgs. 1410-1416 (March 1, 2000).	
	4	Jin Kyu Lee et al., "Cloning and characterization of a mammalian N-acetylglucosamine-6-sulfotransferase that is highly restricted to intestinal tissue," Biochemical and Biophysical Research Communications, Vol. 2, No. 263, pgs. 543-549 (September 1999).	
	5	Kimura et al., "Reconstitution of functional L-selectin ligands on a cultured human endothelial cell line by cotransfection of $\alpha$ -1 $\rightarrow$ 3 fucosyltransferase VII and newly cloned G1cNAc $\beta$ :6-sulfotransferase cDNA," Proceedings of the National Academy of Sciences of USA, Vol. 96, pgs. 4530-4535 (April 1999).	
	6	Seko et al., "Biochemical differences between two types of N-acetylglucosamine: $\rightarrow$ 6sulfotransferases in human colonic adenocarcinomas and the adjacent normal mucosa: specific expression of a G1cNAc: $\rightarrow$ 6sulfotransferase in mucinous adenocarcinoma," Glycobiology, Vol. 10, No. 9, pgs. 919-929 (September 2000).	
	7	Seko et al., "Ectopic expression of a G1cNAc 6-O-sulfotransferase, G1cNAc6ST-2, in colonic mucinous adenocarcinoma," Glycobiology, IRL Press, GB, Vol. 12, No. 6, pgs. 379-388 (2002).	
	8	Streeter et al., "Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes," The Journal of Cell Biology, Vol. 107, No. 5, pgs. 1853-1862 (November 1998)	
	9	Supplementary European Search Report for European Patent Application No. 04747273.3 - 1223 PCT/JP2004009805 dated April 18, 2008.	
	10	Uchimura et al., "Specificities of N-acetylglucosamine-6-O-sulfotransferases in relation to L-selectin ligand synthesis and tumor-associated enzyme expression," Journal of Biological Chemistry, Vol. 277, No. 6, pgs. 3979-3984 (February 8, 2002).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*